ABSTRACT
Background We assessed the association between antibody concentration ≤5 days of symptom onset and COVID-19 illness among patients enrolled in a test-negative study
Methods From October 2021─June 2022, study sites in seven states enrolled and tested respiratory specimens from patients of all ages presenting with acute respiratory illness for SARS-CoV-2 infection using rRT-PCR. In blood specimens, we measured concentration of anti- SARS-CoV-2 antibodies against the ancestral strain spike protein receptor binding domain (RBD) and nucleocapsid (N) antigens in standardized binding antibody units (BAU/mL). Percent reduction in odds of symptomatic COVID-19 by anti-RBD antibody was estimated using logistic regression modeled as (1–adjusted odds ratio of COVID-19)x100, adjusting for COVID-19 vaccination status, age, site, and high-risk exposure.
Results A total of 662 (33%) of 2,018 symptomatic patients tested positive for acute SARS- CoV-2 infection. During the Omicron-predominant period, geometric mean anti-RBD binding antibody concentrations measured 823 BAU/mL (95%CI:690─981) among COVID-19 case- patients versus 1,189 BAU/mL (95%CI:1,050─1,347) among SARS-CoV-2 test-negative patients. In the adjusted logistic regression, increasing levels of anti-RBD antibodies were associated with reduced odds of COVID-19 for both Delta and Omicron infections.
Conclusion Higher anti-RBD antibodies in patients were associated with protection against symptomatic COVID-19 during emergence of SARS-CoV-2 Delta and Omicron variants.
Competing Interest Statement
Dr. Zimmerman reports grants from CDC, during the conduct of the study, and grants from Sanofi Pasteur, outside the submitted work. Dr. Grijalva reports other from CDC, grants from NIH, other from FDA, grants and other from AHRQ, other from Merck, and other from Syneos Health, outside the submitted work. Dr. Talbot reports grants from CDC, during the conduct of the study. All other authors report not conflicts of interest.
Funding Statement
This work was supported by Centers for Disease Control grant numbers 75D30121C11529, 75D30121C12339, 75D30121C12246, 75D30121C11513, 75D30121C12279, 75D30121C11909, 75D30121C11519, National Institutes of Health grant number UL1TR001857, and National Center for Advancing Translational Sciences Clinical Translational Science Award number 5UL1TR002243-03.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of US Centers for Disease Control and Prevention gave ethical approval for this work. The IRB of each US Flu VE Network site gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
All data produced in the present study are available upon reasonable request to the corresponding author.
